Benefit of Romiplostim vs. Standard of Care (SOC) and SOC+Rituximab in ... Monthly Prescribing Reference Eleven of 16 patients in the SOC arm received rituximab 219–363mg/m 2 once weekly for four weeks. In this post hoc, non-randomized comparison, investigators examined outcomes of these 16 patients as compared with the romiplostim group (in which one ... |
